December #87 : Slim Picks - by Laura Whitehorn and Mike Barr

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Baby Love

Fuzeon Fever

Artists With (out) a Cause

Wash 'n' Bear

Adoption Option

Make It a Date

Beijing Surprise

Apocalypse Now

Loan Shark

Fund Frisk

A Tempest in a T Cell

Slim Picks

Fat Skinny

Break Time

Straight Forward

Condoms Inc.

Steppin' Positive


Cinema Variety

Daddy's Dearest

Gift Rap

'Tis the Season

Publisher's Letter


In Vogue

Star Power

‘Tis the Season


Saving It

Getting Cheeky

Fix Is In?

Say What?

Cash Flown!

Full-Frontal Face

Wisdom Of The Ages


Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 2002

Slim Picks

by Laura Whitehorn and Mike Barr

The focus on lipo's emotional toll may prod insurers to pay up

Ho-down aside, neither San Diego's ICAAC nor a just-days-before lipo confab revealed any "paradigm shifts," said San Francisco AIDS doc Stephen Becker. The good news? Up-and-coming HIV meds like T-20 (see "Fuzeon Fever" December 2002). The rest? Mostly old news.

On the lipo front, Project Inform's Martin Delaney said he sat up for a study further ID'ing d4T [Zerit] as a "particular culprit" in fat-loss problems, and another asserting "the combination of ddI [Videx] and d4T is more toxic than others [like AZT plus 3TC]."

Studies showed -- again -- that polylactic acid (New-Fill) injections mask facial fat loss -- though follow-up stopped at 24 weeks. "My take-away," noted National AIDS Treatment Advocacy Project's Jules Levin, "is that surgery benefits appear to fade relatively quickly, requiring additional procedures." Sigh. Bright side? The new focus on the emotional toll lipo exacts from HIVers may prod health insurers to pony up for these so-called "cosmetic" treatments.

File these "same-olds" under H (but not for HIV): Genital herpes transmission is reduced by valacyclovir (Valtrex) -- reportedly the first study to report an antiviral med proving to block a viral STD, though we've long suspected that lowering viral load (HSV or HIV) makes people less contagious. The only new news came from a separate study showing genital herpes (which most HIVers have) still ups the chance of transmitting HIV even when you're not having outbreaks. (So glove it, luv.)

As for new-drug nuggets, POZ scooped the ICAAC PR machine last month on six HIV meds due in 2003 (see "Ahoy, New Meds Ahead!" November 2002). Did San Diego add anything else to the mix? Answering a question POZ posed in that scoop, Levin reports from ICAAC that "Atazanavir (Zrivada) [the two-pills-once-a-day protease inhibitor] hasn't led to increases in cholesterol, triglycerides or glucose, suggesting that [lipo] might be slower to develop." (So now will the "blockbuster marketing" begin?) And Duke's Bryan Cullen, MD, passed on word from ICAAC of "NNRTIs with a much better resistance profile than earlier ones." Example: Tibotec-Virco's TMC-125 -- but it's only in Phase II.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.